Tanner Health System
Dr. Prieschl-Grassauer has more than fifteen years of experience working in pharmaceutical drug development. Dr Prieschl-Grassauer is CSO and Co-founder of Marinomed and graduated Ph.D. from the University of Vienna. Before Marinomed, she was head of the allergy program at Novartis in Vienna. In this position, she discovered the mechanism of action of FTY720 (Fingolimod), Novartis´ novel immunomodulatory drug against multiple sclerosis. Following that, she supervised the clinical development of an innovative cancer therapy drug that was in clinical Phase III. Dr. Prieschl-Grassauer has published more than 30 articles in high ranking peer-reviewed journals in the field of immunology, molecular biology and medicinal chemistry.